focus -WSS

focus

author：knowledge 2025-08-24 10:14:52 - browse：83

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Doctors find melanoma drugs effective against rare brain cancer

focus

WSS

NIH confirmation hearing shows politicization of research

STAT Summit: How a Chicago ER doctor tackles gun violence

First Opinion Podcast: Long Covid needs a new approach

Key House panel plots a new health care package

At Orexo, a ‘turning point’ for everything but digital health

Medicare has a new plan to address drug shortages

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Senate committee scrutinizes Medicare Advantage brokers

ChatGPT in medicine: STAT answers readers' burning questions

Researchers explore possible ties between long Covid, menopause

New air purifier tech could be key to improving indoor air quality

The explosion of genetic testing requires a new approach

Novavax promises a turnaround & Lilly roils the obesity market

STAT Readout Newsletter: Today's biggest biotech updates

Continuity nursing helped my family in our darkest PICU moments

Will Ozempic

focus

Doctors find melanoma drugs effective against rare brain cancer

Biden tests positive for Covid

2023 STAT Wunderkinds: get to know the winners

CEOs share strategies for surviving biotech slump

STAT Summit: Michael J. Fox on progress in Parkinson's research

NIH confirmation hearing shows politicization of research

hotspot

focus

leisure time

explore